Icon (NASDAQ:ICLR) Director Sells $138,167.89 in Stock

Posted by Geri Gentry on Aug 15th, 2026

Icon Plc (NASDAQ:ICLR – Get Free Report) Director Anne Clem Whitaker sold 841 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $138,167.89. Following the sale, the director owned 891 shares of the company’s stock, valued at approximately $146,382.39. This represents a 48.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Price Performance

Shares of ICLR opened at $163.15 on Friday. The business’s fifty day moving average is $162.50 and its 200 day moving average is $134.24. Icon Plc has a 12-month low of $66.57 and a 12-month high of $203.91. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a market cap of $12.49 billion, a P/E ratio of 38.30, a P/E/G ratio of 6.94 and a beta of 1.21.

Icon (NASDAQ:ICLR – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2 billion. During the same quarter in the previous year, the business posted $3.26 EPS. Icon’s quarterly revenue was up 2.3% on a year-over-year basis. Sell-side analysts anticipate that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Mizuho raised their price target on shares of Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Friday, June 26th. Barclays upped their price target on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Citigroup increased their price target on Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. Piper Sandler downgraded shares of Icon to a “neutral” rating in a report on Thursday, May 28th. Finally, Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $170.40.

Read Our Latest Stock Analysis on Icon

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. Wellington Management Group LLP increased its position in shares of Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after purchasing an additional 975,268 shares during the last quarter. Orbis Allan Gray Ltd grew its position in Icon by 1.8% during the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after buying an additional 75,843 shares during the period. Invesco Ltd. grew its position in Icon by 9.6% during the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock valued at $684,582,000 after buying an additional 329,266 shares during the period. Principal Financial Group Inc. raised its position in Icon by 10.3% in the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after acquiring an additional 310,236 shares during the period. Finally, Franklin Resources Inc. raised its position in Icon by 8.7% in the fourth quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock worth $545,410,000 after acquiring an additional 239,808 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Company Profile

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.